US$ 28.50
mash and glp 1 Resmetirom GLP-1 agonists for MASH: complementary rather than exclusive Indications for GLP-1/GIP RA Summary
Description
Weight loss results from the subsequent control of calorie intake

A review of anti-obesity treatments found that semaglutide as well as tirzepatide (which has an overlapping mechanism of action) were more promising than previous anti-obesity drugs, although less effective than bariatric surgery

These therapies are ideal for long-term weight management and body sculpting without the risks of compounded GLP-1 prescriptions

Studies, such as the STEP 4 trial, have shown that while some individuals achieve substantial weight reduction, others may see more modest results due to a combination of factors, including baseline metabolic health, lifestyle habits, and adherence to dietary recommendations

Research Highlights

Semaglutide can cause nausea, vomiting, or diarrhea, potentially leading to dehydration, a known cause of fatigue
